Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103519 · ClinicalTrials.gov registry record · Phase 2
Study of DITPA in Patients With Congestive Heart Failure
A Phase 2 study, sponsored by Titan Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT00103519: Clinical Trial Phase 2 study, sponsored by Titan Pharmaceuticals.
NCT00103519 is a Phase 2 study that was terminated before completion, run by Titan Pharmaceuticals. The registered enrollment target is 86 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00103519, a Phase 2 study, was terminated before completion, sponsored by Titan Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of DITPA relative to placebo in patients with New York Heart Association (NYHA) class III or IV congestive heart failure (CHF) who have low serum T3. DITPA is an investigational agent.
Interventions
- DRUG Placebo
- DRUG DITPA (3,5-diiodothyropropionic acid)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2004-12 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Why NCT00103519 stopped before completion
NCT00103519 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00103519 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00103519 about?
NCT00103519 is a clinical study titled "Study of DITPA in Patients With Congestive Heart Failure". This study will assess the safety and efficacy of DITPA relative to placebo in patients with New York Heart Association (NYHA) class III or IV congestive heart failure (CHF) who have low serum T3. DITPA is an investigational agent.
What is the current status of trial NCT00103519?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2004-12. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00103519?
The interventions under investigation include: Placebo (DRUG), DITPA (3,5-diiodothyropropionic acid) (DRUG).
Who is sponsoring clinical trial NCT00103519?
This trial is sponsored by Titan Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00103519's enrollment target sits among peer trials
86 812th of 2000 higher than 1,181 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia